Decheng Capital Llc

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$661.3M
Q ending 2026-03-31
Prior quarter
$743.4M
Q ending 2025-12-31
Change
-11.0% QoQ · +85.5% YoY
Positions
14
reported holdings

Largest positions

All 14 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Cg Oncology IncCGONShares$431.2M6.4M
Nuvation Bio Inc.NUVBShares$111.3M26.0M
Upstream Bio Inc.UPBShares$24.5M2.7M
Aclaris Therapeutics, Inc.ACRSShares$15.2M4.0M
Aardvark Therapeutics IncAARDShares$14.8M3.9M
Lyell Immunopharma, Inc.Shares$13.9M692K
Newamsterdam Pharma Co NvShares$10.4M325K
Arcus Biosciences, IncRCUSShares$10.3M478K
Revolution Medicines Inc(Nsm)RVMDShares$9.1M94K
Equillium Inc.EQShares$8.9M4.4M
Beyondspring Inc.Shares$6.2M3.8M
Zentalis Pharmaceuticals Inc.ZNTLShares$3.1M1.3M
Krystal Biotech IncKRYSShares$1.9M7K
Pyxis Oncology, Inc (Formerly ApexPYXSShares$477K327K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.